By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that its first-quarter 2010 net loss swelled 18 percent, as the firm's expenses for R&D, sales, and other purposes rose but its revenues continued to be insignificant.

The Tel Aviv, Israel-based firm, which uses an in silico prediction and selection platform for discovering drug and diagnostic candidates, had revenues of $125,000 for the three-month period ended Mar. 31, compared to no revenue for last year's first quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.